Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

葛根素衍生物及其醫學用途


總結

The invention relates to a novel application of puerarin and derivates thereof in the pharmaceutical field. The puerarin and the derivates thereof have a COX-2-selective inhibition effect, are safe in use without toxic side effect, and have notable effectiveness. The puerarin and the derivates thereof can be used to prevent and cure osteoarthritis, rheumatic arthritis, rheumatoid arthritis, urarthritis, hepatitis, conjunctivis, myocarditis, secondary inflammations caused by tumor and diabetes, itai itai diseases caused by cold or trauma, and other difficult and baffling diseases.


附加資料

Inventor: Albert Sun-chi Chan | Shi Lin Chen | Yueming Li | Dajian Yang
Priority Number: CN100572374C
IPC Current: C07D031134 | A61K0031352 | A61K00317048 | A61P000306 | C07H001707
Assignee Applicant: Hong Kong Jockey Club Inst Chinese Medic
Title: Puerarin derivatives and their medical uses | Puerarin derivative and its medical use
Usefulness: Puerarin derivatives and their medical uses | Puerarin derivative and its medical use
Summary: (I) are useful to treat myocardial ischemia and for modulating blood lipid levels, dilating coronary and cerebral arteries, reducing oxygen consumption of cardiomyocytes, improving microcirculation and preventing aggregation of blood platelets. The method is useful for enhancing the bioavailability of (I) (all claimed). The ability of (I) to treat myocardial ischemia was tested in rats by inducing acute myocardial ischemia by injection of posterior pituitary extract and treatment with varying concentrations of (I) with propranolol as a positive control. T-wave amplitude variation was measured post-injection by ECG and compared with untreated controls. For animals treated with 1.28 g/kg hexa-acetylpuerarin 15 seconds post injection, T-wave amplitude was 29.09 ± 16.50 μV, compared with 105.23 ± 33.09 μV for the untreated control and 18.51 ± 9.26 μV for the positive control.
Novelty: New puerarin derivatives, useful e.g. to treat myocardial ischemia, modulate blood lipid levels, dilating coronary and cerebral arteries and reduce oxygen consumption of cardiomyocytes


主要類別

化工/材料


細分類別

化工/材料應用


其他

楊大堅
李月明
陳士林
陳新滋


國家/地區

中國內地

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版